国产日韩欧美,日韩在线中文字幕有码中文,日本妇人成熟免费,欧美牲交作爱在线aav

EN| News Releases
News Releases

News Releases

Home>News Releases
China Resources Pharmaceutical Enters into Strategic Cooperation</br>Agreement with Tianmai Biotech

Press time:2016-12-01From:CR Pharma [Font:BigMediumSmall]

China Resources Pharmaceutical Group Limited (hereinafter “CR Pharma”) signed a legally binding strategic cooperation agreement with Hefei Tianmai Biotechnology Development Co. Ltd. (hereinafter “Tianmai Biotech”) on November 30th, 2016. Under the cooperation agreement, both parties are to commence in-depth cooperation in the field of recombinant human insulin leveraging their respective strengths to develop recombinant insulin protein technology and product lines. This marks a major milestone in CR Pharma’s strategic development in the biopharmaceutical area.

As a biopharmaceutical company focusing on the R&D, production and sales of a series of insulin products, Tianmai Biotech has a well-established roadmap for insulin product lines. It has completed the development of technologies and products in relation to the second generation recombinant human insulin and third generation long-acting insulin analogs (including insulin glargine and a new type of long-acting insulin analog) in China. Among which, the R&D of its second-generation recombinant human insulin is at the forefront among the manufacturers of the drug. It has applied for the Certificate of Commercial Production in relation to recombinant human insulin injections, which are expected to be launched in 2017. Meanwhile, Tianmai Biotech has planned the course of development for the third generation rapid-acting insulin analogs such as insulin aspart and insulin lispro.

According to the statistics of IMS Health Inc. (“IMS”), a leading global market intelligence resources company specializing in the pharmaceutical and healthcare industries, the global market for insulin exceeded US$20 billion in 2014, with the domestic market in China accounting for approximately US$1.5 billion. IMS expects that by 2030, the global market for insulin will reach US$63 billion while China’s market will be around US$12 billion. Thus, insulin continues to enjoy strong market demand with immense growth potential in the future. Moreover, the trend of domestically manufactured products gradually replacing imported brands has been well established. CR Pharma believes the strategic cooperation with Tianmai Biotech enables both parties to realize their respective advantages in resources and technology so as to further broaden the insulin product offerings in Mainland China. They will collaborate to explore opportunities of the insulin market in Mainland China and to develop Tianmai Biotech into an outstanding Chinese enterprise in the insulin area.

Back to Top
      
      

      <ul id="9ehld"></ul>
      
      <bdo id="9ehld"></bdo>

    1. 主站蜘蛛池模板: 个旧市| 宜城市| 宽城| 南木林县| 肇州县| 丰镇市| 冷水江市| 大丰市| 兴隆县| 汨罗市| 蒙阴县| 酒泉市| 莲花县| 宝应县| 漳浦县| 凤阳县| 漠河县| 焉耆| 镇雄县| 抚宁县| 疏勒县| 西畴县| 朝阳县| 屯昌县| 运城市| 海晏县| 阳西县| 棋牌| 会昌县| 博湖县| 应用必备| 沾化县| 湖口县| 永城市| 陆良县| 清镇市| 抚远县| 昌吉市| 襄城县| 和顺县| 郧西县|